An Integrative Approach to the Patient with Thrombophilia / SVEOBUHVATNI PRISTUP BOLESNIKU SA TROMBOFILIJOM

Open access


Venous thromboembolism (VTE) is a multifactorial disease that results from a conjunction of several risk factors, both inherited and acquired. The younger the person, the more risk factors are required to cause the disease. Since 1937, when the term thrombophilia was coined by Nygaard and Brown, and 1965 when it was used for the first time by Egeberg, a substantial increase in the percentage of patients with VTE and underlying thrombophilia has been reported, particularly after the discovery of the most common thrombophilic mutations, FV Leiden and FII G20210A. Presence of thrombophilia could be detected in as many as 50% of all patients with VTE. Thrombophilia testing has increased lately not only in patients with thromboses but also for other indications, however, whether the results will help in the clinical management of the patients is still unclear. Thrombo philia testing is most commonly performed in young patients with VTE, patients with recurrent episodes of VTE or with thromboses at unusual sites and in persons with positive family history. Whether the presence of thrombophilia influences the clinical management of the patient remains controversial. Patients with VTE and the recognized risk factors such are surgery, trauma, immobilization, pregnancy and the puerperium are at very low risk for recurrence, but prediction of the recurrence of VTE based on the presence of thrombophilia has not been sufficiently explored. Presence of clinical risk factors should be integrated in the strategy of VTE risk assessment. Since many risk factors, such as obesity, hypertension, dyslipidemia, diabetes and smoking are common for both arterial and venous thromboses, it has been suggested that VTE should be considered as part of a pancardiovascular syndrome, along with coronary artery disease, peripheral artery disease and cerebrovascular disease. Positive family history for VTE in a first-degree relative increases the risk for VTE occurrence by 2-fold, regardless of the presence of inherited thrombophilia. Pregnancy-related risk of VTE is sixfold in creased compared to nonpregnant age-matched women. Women with thrombophilia have been shown to be at an increased risk not only of pregnancy-associated thromboembolism, but also of other vascular complications, including recurrent fetal loss and intrauterine fetal death. Risk for antepartal pregnancy-related VTE is considerably increased in obese women confined to bed for longer than one week, in women who underwent assisted reproduction, in multiple pregnancies, gestational diabetes and maternal age over 35 years. Postpartal risk factors differ, with eclampsia, emergency cesarian section and placenta praevia being the most important. Testing for thrombophilia generally does not alter the management of a patient with VTE, except for selected groups of patients. Women of fertile age with positive family history and presence of thrombophilia may benefit from thromboprophylaxis implementation during pregnancy, or can make the decision not to use oral contraceptives. In the future, the use of global coagulation tests that could detect a hypercoagulable state, along with other clinical risk factors, might improve VTE risk assessment and optimize the duration of treatment of VTE disease.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Nygaard KK Brown GE. Essential thrombophilia: report of five cases. Arch Intern Med 1937; 59: 82-106.

  • 2. Prandoni P Lensing AWA Cogo A Cuppini S Villalta S Carta M Catellan AM Polistena P Bernardi E Prins MH. The long term clinical course of acute deep venous thrombosis. Ann Int Med 1996 125(1): 1-7.

  • 3. Hansson PO Sörbo J Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Archives of Internal Medicine 2000; 160: 769-74.

  • 4. Baglin T Luddington R Brown K Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6. 5 . Christiansen SC Cannegieter SC Koster T Vandenbroucke JP Rosendaal FR. Thrombophilia clinical factors and recurrent venous thrombotic events. Journal of the American Medical Association 2005; 293: 2352-61. 6 . Prandoni P Noventa F Ghirarduzzi A Pengo V Ber nardi E Pesavento R Lotti M Tormene D Simioni P Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1 626 patients. Haema tologica 2007; 92: 199-205.

  • 7. Eischer L Eichinger S Kyrle PA. Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. Medicine (Baltimore) 2009; 88: 366-70.

  • 8. Keeling D. Duration of anticoagulation: a decision making based on absolute risk. Blood Rev 2006; 20: 173-8.

  • 9. Dahabreh IJ Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011; 139: 893-900.

  • 10. Baglin T. Unrevealing the thrombophilia paradox: from hypercoagulability to the prothrombotic state. J Thromb Haemost 2010; 8: 2159-68.

  • 11. Heit JA Mohr DM Silverstein MD Petterson TM O’Fallon WM Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population based cohort study. Arch Int Med 2000; 160: 761-8.

  • 12. De Stefano V Simioni P Rossi E Tormene D Za T Pagnan A Leone G. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin protein C and protein S. Haematologica 2006; 91(5): 695-8.

  • 13. Coppens M Reijnders JH Middeldorp S Doggen CJ Rosendaal FR. Testing for inherited thrombophilia does not reduce recurrence of venous thrombosis. J Thromb Haemost 2008; 6: 1474-7.

  • 14. Mahmoodi BK Brouwer JL Ten Kate MK Lijfering WM Veeger NJ Mulder AB Kluin-Nelemans HC van der Meer J. A prospective cohort study on the absolute risk of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S protein C or antithrombin. J Thromb Haemost 2010; 8: 1193-200.

  • 15. Simioni P Prandoni P Lensing AWA Manfrin D Tormene D Gavasso S Girolami B Marchiori A Sardella C Prins M Girolami A. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96: 3329-33. 16 . Miles JS Miletich JP Goldhaber SZ Hennekens CH Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001; 37: 215-18.

  • 17. Brouwer JL Lijfering WM Ten Kate MK Kluin-Nelemans HC Veeger NJ van der Meer J. High ling-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of proten S protein C and antithrombin. Haemost Thromb 2009; 101: 93-9.

  • 18. Vossen CY Walker ID Svensson P Souto JC Scharrer I Preston FE Palaretti G Pabinger I van der Meer FJ Macris M Fontcuberta J Conard J Rosendaal FR. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Atheroscl Thromb Vasc Biol 2005; 25: 1992-7.

  • 19. Middeldorp S van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008; 143: 321-35.

  • 20. Lijfering WM Brouwer JL Veeger NJ Bank I Coppens M Middeldorp S Hamulyak K Prins MH Buller HR van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-22.

  • 21. Palareti G Cosmi B Legnani C Tosetto A Brusi C Iorio A Pengo V Ghiraduzzi A Pattacini C Testa S Lensing AW Tripodi A; PROLONG investigators. D-dimer testing to determine the duration of anticoagulant therapy. N Eng J Med 2006; 355(17): 1780-9.

  • 22. Kemmeren JM Algra A Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta analysis. BMJ 2001; 323(7305): 131-4.

  • 23. Jick H Jick SS Gurewich V Myers MW Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.

  • 24. Farmer RD Lawrenson RA Thompson CR Kennedy JG Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.

  • 25. Middeldorp S. Thrombosis in women: what are the know ledge gaps in 2013. J Thromb Haemost 2013; 11(Suppl. 1): 180-91.

  • 26. Naess IA Christiansen SC Romundstad P Cannegieter SC Rosendaal FR Hammerstrom J. Incidence and mortality of venous thrombosis: a population based study. J Thromb Haemost 2007; 4: 692-9.

  • 27. Van Hylckama Vlieg A Helmerhorst FM Vandenbroucke JP Doggen CJ Rosendaal FR. The venous thrombotic risk of oral contraceptives effects of oestrogen dose and progesterone type: results of MEGA case-control study. BMJ 2009 339: b2921.

  • 28. Vandenbroucke JP Koster T Briet E Reitsma PH Bertina RM Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.

  • 29. Martinelli I Taioli E Bucciarelli P Akhavan S Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep venous thrombosis. Atheroscl Thromb Vasc Biol 1999; 19: 700-3.

  • 30. Bloemenkamp KW Helmerhorst FM Rosendaal FR Vandenmbroucke JP. Venous thrombosis oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 128: 15-20.

  • 31. Martinelli I Sacchi E Landi G Teioli E Duca F Mannucci PM. High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7.

  • 32. De Bruijn SF Stam J Vandenbroucke JP. Increased risk of cerebral venous thrombosis with third generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet 1998; 351: 1404.

  • 33. Farley TM Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998; 57: 211-30.

  • 34. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke overall stroke risk and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1996; 348: 505-10.

  • 35. Daly E Vessey MP Hawkins MM Carson JL Gough P Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.

  • 36. Jick H Derby LE Myerss MW Vasilakis C Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-3.

  • 37. Perez-Gutthann S Garcia Rodriguez LA Castelsague JC Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case control study. BMJ 1997; 314: 796-800.

  • 38. De Sancho MT Dorff T Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coag Fibrinolysis 2010; 21: 534-8.

  • 39. Cushmen M Kuller LH Prentice R Rodabough RJ Psaty BM Stafford RS Sidney S Rosendaal FR. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292(13): 1578-80.

  • 40. Canonico M Oger E Plu-Bureau G Conard J Meyer G Lévesque H Trillot N Barrellier MT Wahl D Emmerich J Scarabin PY. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-5.

  • 41. Bonnar J. Haemostasis and coagulation disorders in pregnancy. In: Bloom AL Thomas DP eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1987: 570-84.

  • 42. Bremme K. Haemostasis in normal pregnancy. In: Brenner B Marder VJ Conard J eds. Women’s Issues in Haemostasis and Thrombosis. London: Martin Dunitz Ltd; 2002: 151-65.

  • 43. McColl MD Ramsay JE Tait RC Walker ID McCall F Conkie JA Carty MJ Greer IA. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.

  • 44. Eldor A. Thrombophilia thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-11.

  • 45. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.

  • 46. Jacobsen AF Skjeldestad FE Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008; 198: 233.

  • 47. Blanco-Molina A Trujillo-Santos J Criado J Lopez L Lecumberri R Gutierrez R Monreal M. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE registry. Thromb Haemost 2007; 97: 186-90.

  • 48. Mitić G Kovač M Jurišić D Đorđević V Ilić V Salatić I Spasić D Novakov Mikić A. Clinical characteristics and type of thrombophilia in women with pregnancy-related venous thromboembolic disease. Gynecol Obstet Invest 2011; 72(2): 103-8.

  • 49. Mitić G Povazan Lj Lazić R Spasić D Maticki-Sekulić M. Deficiency of the natural anticoagulant proteins in women with pregnancy related venous thromboembolism. Med Pregl 2009 Jan-Feb; 62(1-2): 53-62.

  • 50. Mitić G Povazan L Lučić AM. Treatment of pregnancy related venous thromboembolism. Med Pregl 2009 Jul- Aug; 62(7-8): 346-51.

  • 51. Robertson L Wu O Langhorne P Twaddle S Clark P Lowe GDO Walker ID Greaves M Brenkel L Regan Greer IA. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132(2): 171-96.

  • 52. Bates SM Greer IA Middeldorp S Veenstra D Prabulus AM Vandvik PO. Venous thromboembolism thrombophilia antithrombotic therapy and pregnancy: ACCP evidence based clinical practice guidelines. Chest 2012; 2(Suppl): e691S-736S.

  • 53. Mitić G. Nasledna trombofilija i trombozne komplikacije u trudnoći (disertacija). Novi Sad: Univerzitet u Novom Sadu; 2008; 128.

  • 54. Friederich PW Sanson BJ Simioni P Zanardi S Huisman MV Kindt I Prandoni P Buller HR Girolami A Prins MH. Frequency of pregnancy related venous thromboembolism in anticoagulant factor deficient women: implications for prophylaxis. Ann Int Med 1996; 125: 955-60.

  • 55. Brenner B Hoffman R Blumenfeld Z Weiner Z Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.

  • 56. Brenner B Hoffman R Carp H Dulitzky M Younis JS. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3: 227-9.

  • 57. Carp H Dolitzky M Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-8.

  • 58. Gris JC Mercier E Quere I Lavigne-Lissalde G Cochery- Nouvellon E Hoffet M et al. Low molecular weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.

  • 59. Visser J Ulander VM Helmerhorst FM Lampinen K Morin-Papunen L Bloemenkamp KWM Kaaja RJ. Throm boprophylaxis for recurrent miscarriage in women with or without thrombophilia HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105: 295-301.

  • 60. Clark P Walker ID Langhorne P Crichthon L Thomson A Greaves M Whyte S Greer IA. SPIN: the Scottish Pregnancy Intervention Study: a multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010; 115: 4162-7.

  • 61. De Vries JI van Pampus MG Hague WM Bezemer PD Joosten JH. Low molecular weight heparin added to aspirin in the prevention of the early onset preeclampsia in women with inheritable thrombophilia: the FRUITRCT. J Thromb Haemost 2012; 1: 64-72.

  • 62. Martinelli I Ruggenenti P Cetin I Pardi G Perna A Vergani P Acaia B Facchinetti F La Sala BG Bozzo M Rampello S Marozio L Diadei O Gherardi G Carminati S Remuzzi G Mannucci PM. Heparin in pregnant women with previous placenta mediated pregnancy complications: a prospective randomized multicenter controlled clinical trial. Blood 2012; 14: 3269-75.

  • 63. Mitić G Kovač M Povazan L Magić Z Đorđević V Salatić I Mitić I Novakov-Mikić A. Inherited thrombophilia is associated with pregnancy losses that occur after 12th gestational week in Serbian population. Clin Appl Thromb Hemost 2010 Aug; 16(4): 435-9.

  • 64. Kovač M Mitić G Miković Z Đorđević V Savić O Mandić V Rakičević LJ Antonijević N Radojković D. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancy-related venous thromboembolism. Gynecol Obstet Invest 2010; 69(4): 233-8.

  • 65. Mitić G Novakov Mikić A Povazan L Mitreski A Ko pitović V Vejnović T. Thromboprophylaxis implementation during pregnancy in women with recurrent fetal losses and thrombophilia. Med Pregl 2011 Sep-Oct; 64 (9-10): 471-5.

  • 66. Kovač M Miković Z Mitić G Đorđević V Mandić V Rakičević L Radojković D. Does anticoagulant therapy improve pregnancy outcome equally regardless of specific thrombophilia type? Clin Appl Thromb Hemost. 2013 Jan 15. [Epub ahead of print] PMID: 23262970.

  • 67. Koster T Rosendaal FR Briet F van dr Meer FJ Colly LP Trienekens PH Poort SR Reitsma PH Vandenbroucke JP. Protein C deficiency in uncontroled series of unselected outpatients: an unfrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85(10): 2756-61.

  • 68. Simioni P Sanson BJ Prandoni P Tormene D Friedwrich PW Girolami B Gavasso S Huisman MV Büller HR Wouterten Kate J Girolami A Prins MH. Incidence of venous thromboembolism in families with inherited throm bophilia. Thromb Haemost 1999; 81: 198-202.

  • 69. Ageno W Becattini C Brighton T Selby Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.

  • 70. Abdollahi M Cushman M Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89(3): 493-8.

  • 71. Blom JW Doggen CJM Osanto S Rosendaal FR. Malignancies prothrombotic mutations and the risk of venous thrombosis. JAMA 2005; 293(6): 715-22.

  • 72. Majkić-Singh N Šumarac Z. Quality Indications of the Pre-Analytical Phase. J Med Biochem 2012; 31: 174-83.

  • 73. Doggen CJM Cats VM MD Bertina RM Rosendaal FR. Interaction of Coagulation Defects and Cardiovascular Risk Factors: Increased Risk of Myocardial Infarction Asso ciated With Factor V Leiden or Prothrombin 20210A. Circulation 1998; 97: 1037-41.

  • 74. Prandoni P Bilora F Marchiori A Bernardi E Petrobelli F Lensing AW Prins MH Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.

  • 75. Spencer FA Ginsberg JS Chong A Alter DA. The relationship between unprovoked venous thromboembolism age and acute myocardial infarction. J Thromb Haemost 2008; 6: 1507-13.

  • 76. Sorensen HT Horvath-Puho E Pedersen L Baron JA Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-9.

Journal information
Impact Factor

IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 211 152 1
PDF Downloads 88 63 2